Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
This study has been completed.
Study NCT00046930 Information provided by Eastern Cooperative Oncology Group
First Received on October 3, 2002. Last Updated on June 21, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Anemia
Anemia, Aplastic
Anemia, Refractory
Anemia, Refractory, with Excess of Blasts
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Preleukemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Precancerous Conditions
Interventions listed in this trial
filgrastim
sargramostim
cytarabine
daunorubicin hydrochloride
zosuquidar trihydrochloride
Placebo
Additional drug interventions recognized in this trial
Daunorubicin
Lenograstim
More general drug interventions related to this trial
Adjuvants, Immunologic
Anti-Infective Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Eli Lilly and Company
Kanisa Pharmaceuticals
Back to top of Main Content
